Effect of alendronte treatment on bone tunover - Results of a multicentre study;Vplyv liecby alendronatom na kostny obrat - Vysledky multicentrickej studie

Vnitrni Lekarstvi

Volumn 46, Issue 10, 2000, Pages 689-692

  Payer J , Jr ^a   Killinger, Z ^a   Masaryk, P ^a   Tomkova, S ^a   Kmecova, Z ^a   Ondrejkova, J ^a   Necas, L ^a   Smoterova, J ^a   Ondrejka, P ^a   Kratochvilova, H ^a  

^a I Interna Klinika   (Slovakia)

Author keywords

N telopeptide (NTx); Osteoporosis; Sodium alendronate

Indexed keywords

ALENDRONIC ACID; CALCIUM; BIOLOGICAL MARKER; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PEPTIDE;

ADULT; ARTICLE; BONE DENSITY; BONE REMODELING; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OSTEOLYSIS; PATHOGENESIS; PATHOLOGIC FRACTURE; POSTMENOPAUSE OSTEOPOROSIS; AGED; DRUG EFFECT; MIDDLE AGED; PATHOPHYSIOLOGY; URINE;

ADULT; AGED; ALENDRONATE; BIOLOGICAL MARKERS; BONE REMODELING; BONE RESORPTION; CALCIUM; COLLAGEN; COLLAGEN TYPE I; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES;

EID: 0033752421     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
2. Effect of alendronate on risk of fracture in women with low bon density without vertebral fractures. Results from the fracture intervention trial
3. The role of markers of bone turnover in the assessment of fracture risk in postmenopausal women
4. Oral alendronate induced progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis
5. Treatment with alendronate presents fractures in women at highest risk. Results from the Fracture Intervention Trial
6. Bisphosphonates in bone diseases
7. Bisphosphonates in the treatment of osteoporosis in 1997: A review Current Therapeutic Research
8. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age
9. Preventions of nonvertebral fractures by alendronate : A meta - Analysis
10. Effect of oral alendronate on bone mineral density and the incidence of fracture in postmenopausal osteoporosis
11. The effects of alendronate on bone turnover and bone quality
12. Alendronate treatment of osteoporosis in men
13. Osteoporosis: Review of the evidence for prevention, diagnosis and treatment and cost - Effectiveness analysis. Status report
14. Multinational, placebo-controlled randomised trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study
15. Alendronate for the prevention and treatment of glucocorticoid induced osteoporosis
16. The antifracture efficasy of alendronate
17. Bisfosfonaty